Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - AU
The Guardian - AU
Politics
Melissa Davey Medical editor

Alzheimer’s ‘breakthrough’ stalls: why a much-hyped drug is facing approval delays

Clinical research to develop a possible cure for Alzheimers and dementia in the lab
The Food and Drug Administration has delayed approval of Alzheimer’s drug donanemab and wants a panel to scrutinise safety and efficacy data. Photograph: Tek Image/Science Photo Library/Getty Images

It was heralded in news articles as a “breakthrough”, a “turning point” and a “gamechanger” for Alzheimer’s disease. Some experts went so far as to call the drug, donanemab, the “beginning of the end” for the debilitating condition.

Pharmaceutical company Eli Lilly in May 2023 released data from a clinical trial they said showed donanemab slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease by 35% over 18 months.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.